ERADICATE phase 3 study results highlight the potential
Late breaker presentation at IDWeek 2022First double-blind registrational phase 3 study in Staphylococcus aureus bacteremiaCeftobiprole non-inferior to...
Source: globenewswire.com
Ivan Titov News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Ivan Titov. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Ivan Titov Today - Breaking & Trending Today
Basilea Pharmaceutica AG: Basilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus bacteremia (SAB) at IDWeek 2022
First presentation of ERADICATE phase 3 study dataStudy met its primary and secondary endpoints comparing ceftobiprole versus daptomycin with or without aztreonam Basel/Allschwil, Switzerland, October
Source: finanznachrichten.de